Nadroparin use in critically ill patients on the ICU ward: safe and steady form of coagulation?

Nadroparin use in critically ill patients on the ICU ward: safe and steady form of coagulation? - Nadroparin safe and steady form of anticoagulation?

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33800

Enrollment

120

Registered

2009-02-06

Start date

2009-07-19

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bleeding diathesis hemostasis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Patient with minimum age of 18 years and expected admission time on the ICU of minimum of 48 hours 2. Patient with prophylactic or therapeutic dosage of nadroparin daily

Exclusion criteria

Exclusion criteria: 1. thrombocytopenia (

Design outcomes

Primary

Measure	Time frame
Anti-Xa activity	—

Secondary

Measure	Time frame
Bleeding diathesis Thrombosis	—

Countries

Netherlands

Outcome results